Every drug CMS has selected for Medicare price negotiation so far, 40 in all, with the negotiated price, list price and discount from CMS's own fact sheets. For the drugs this site tracks, the last column shows when US generics or biosimilars arrive.
| Drug | Treats | Negotiated price | Medicare spend (Nov 2024 to Oct 2025) | US copies |
|---|---|---|---|---|
| TrulicityEli Lilly | Type 2 diabetes | Due by 30 Nov 2026 | $4.9B617k patients | US biosimilars 2027 |
| BiktarvyGilead | HIV-1 | Due by 30 Nov 2026 | $3.9B101k patients | US generics 2036 (8 yr after) |
| OrenciaBristol Myers Squibb | Rheumatoid arthritis; psoriatic arthritis | Due by 30 Nov 2026 | $2.5B72k patients | Not tracked |
| CosentyxNovartis | Psoriasis; psoriatic arthritis | Due by 30 Nov 2026 | $2.3B40k patients | US biosimilars 2029 (1 yr after) |
| ErleadaJohnson & Johnson | Prostate cancer | Due by 30 Nov 2026 | $1.9B19k patients | US generics 2033 (5 yr after) |
| KisqaliNovartis | Breast cancer | Due by 30 Nov 2026 | $1.6B17k patients | US generics 2031 (3 yr after) |
| EntyvioTakeda | Crohn's disease; ulcerative colitis | Due by 30 Nov 2026 | $1.5B37k patients | US biosimilars 2032 (4 yr after) |
| VerzenioEli Lilly | Breast cancer | Due by 30 Nov 2026 | $1.4B15k patients | US generics 2031 (3 yr after) |
| BotoxAbbVie | Chronic migraine; overactive bladder; spasticity | Due by 30 Nov 2026 | $1.1B390k patients | Not tracked |
| LenvimaEisai / Merck | Thyroid, endometrial, liver and kidney cancer | Due by 30 Nov 2026 | $1.1B10k patients | Not tracked |
| XolairRoche / Novartis | Asthma; chronic spontaneous urticaria | Due by 30 Nov 2026 | $1.1B40k patients | US biosimilars launched 2026 |
| RexultiOtsuka / Lundbeck | Depression; schizophrenia; Alzheimer's agitation | Due by 30 Nov 2026 | $1.1B119k patients | Not tracked |
| XeljanzPfizer | Rheumatoid arthritis; psoriatic arthritis; ulcerative colitis | Due by 30 Nov 2026 | $1.0B22k patients | Not tracked |
| Anoro ElliptaGSK | COPD | Due by 30 Nov 2026 | $0.8B281k patients | Not tracked |
| CimziaUCB | Crohn's disease; psoriasis; arthritis | Due by 30 Nov 2026 | $0.8B38k patients | Not tracked |
Part B and Part D. The first cycle to include Part B drugs, given in a doctor's office or clinic. CMS also selected Tradjenta (2027 price) for renegotiation. Source: CMS: drugs selected for 2028
| Drug | Treats | Negotiated price (30-day supply) | Below list | Medicare spend (2024) | US copies |
|---|---|---|---|---|---|
| Ozempic / Rybelsus / WegovyNovo Nordisk | Type 2 diabetes; cardiovascular disease; obesity | $274list $959 | −71% | $15.2B2.3M patients | US generics 2032 (5 yr after) |
| Trelegy ElliptaGSK | Asthma; COPD | $175list $654 | −73% | $5.3B1.3M patients | US generics 2027 |
| XtandiAstellas / Pfizer | Prostate cancer | $7,004list $13,480 | −48% | $3.4B35k patients | US generics 2027 |
| PomalystBristol Myers Squibb | Kaposi sarcoma; multiple myeloma | $8,650list $21,744 | −60% | $2.2B14k patients | US generics launched 2026 |
| OfevBoehringer Ingelheim | Idiopathic pulmonary fibrosis | $6,350list $12,622 | −50% | $2.1B24k patients | Not tracked |
| IbrancePfizer | Breast cancer | $7,871list $15,741 | −50% | $2.0B16k patients | US generics 2027 |
| LinzessAbbVie | Chronic constipation; IBS with constipation | $136list $539 | −75% | $2.0B632k patients | Not tracked |
| CalquenceAstraZeneca | CLL/SLL; mantle cell lymphoma | $8,600list $14,228 | −40% | $1.7B15k patients | US generics 2032 (5 yr after) |
| Austedo / Austedo XRTeva | Huntington's chorea; tardive dyskinesia | $4,093list $6,623 | −38% | $1.7B27k patients | Not tracked |
| Breo ElliptaGSK | Asthma; COPD | $67list $397 | −83% | $1.4B626k patients | Not tracked |
| XifaxanSalix (Bausch Health) | Hepatic encephalopathy; IBS with diarrhea | $1,000list $2,696 | −63% | $1.2B105k patients | Not tracked |
| VraylarAbbVie | Bipolar I; major depression; schizophrenia | $770list $1,376 | −44% | $1.1B118k patients | US generics 2029 (2 yr after) |
| TradjentaBoehringer Ingelheim | Type 2 diabetes | $78list $488 | −84% | $1.1B274k patients | Not tracked |
| Janumet / Janumet XRMerck | Type 2 diabetes | $80list $526 | −85% | $1.1B239k patients | Not tracked |
| OtezlaAmgen | Psoriasis; psoriatic arthritis; Behçet's oral ulcers | $1,650list $4,722 | −65% | $1.0B31k patients | US generics 2028 (1 yr after) |
Part D. Prices take effect on 1 January 2027. Source: CMS: negotiated prices for 2027
| Drug | Treats | Negotiated price (30-day supply) | Below list | Medicare spend (2023) | US copies |
|---|---|---|---|---|---|
| JanuviaMerck | Diabetes | $113list $527 | −79% | $4.1B843k patients | US generics launched 2026 |
| Fiasp / NovoLogNovo Nordisk | Diabetes | $119list $495 | −76% | $2.6B785k patients | Not tracked |
| FarxigaAstraZeneca | Diabetes; heart failure; chronic kidney disease | $179list $556 | −68% | $4.3B994k patients | US generics launched 2026 |
| EnbrelAmgen | Rheumatoid arthritis; psoriasis; psoriatic arthritis | $2,355list $7,106 | −67% | $3.0B48k patients | US biosimilars 2029 (3 yr after) |
| JardianceBoehringer Ingelheim | Diabetes; heart failure; chronic kidney disease | $197list $573 | −66% | $8.8B1.9M patients | US generics 2029 (3 yr after) |
| StelaraJohnson & Johnson | Psoriasis; psoriatic arthritis; Crohn's disease; ulcerative colitis | $4,695list $13,836 | −66% | $3.0B23k patients | US biosimilars launched 2025 |
| XareltoJohnson & Johnson | Blood clots; coronary or peripheral artery disease | $197list $517 | −62% | $6.3B1.3M patients | US generics launched 2025 |
| EliquisBristol Myers Squibb | Blood clots | $231list $521 | −56% | $18.3B3.9M patients | US generics 2028 (2 yr after) |
| EntrestoNovartis | Heart failure | $295list $628 | −53% | $3.4B664k patients | US generics launched 2025 |
| ImbruvicaAbbVie / Johnson & Johnson | Blood cancers | $9,319list $14,934 | −38% | $2.4B17k patients | US generics 2032 (6 yr after) |
Part D. Prices take effect on 1 January 2026. Source: CMS: negotiated prices for 2026
For 11 of the 25 drugs this site tracks, US generics or biosimilars arrive no later than the Medicare price: Januvia, Farxiga, Stelara, Xarelto, Entresto, Trelegy, Xtandi, Pomalyst, Ibrance, Trulicity, Xolair. For these, generic or biosimilar competition arrives before or alongside the negotiated price.
The widest gaps, where the Medicare price is the first real pressure on US revenue: Biktarvy (2028 price, copies 2036), Imbruvica (2026 price, copies 2032), Ozempic (2027 price, copies 2032), Calquence (2027 price, copies 2032), Erleada (2028 price, copies 2033).